Baseline decision making capacity in the CATIE schizophrenia trial

被引：0
|
作者：
Stroup, TS [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
来源：
SCHIZOPHRENIA RESEARCH | 2004年 / 67卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：209 / 209
页数：1
相关论文
共 50 条
  • [1] Longitudinal decision making capacity in the CATIE schizophrenia trial
    Stroup, TS
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 284 - 285
  • [2] Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial
    Stroup, S
    Appelbaum, P
    Swartz, M
    Pate, M
    Davis, S
    Jeste, D
    Kim, S
    Keefe, R
    Manschreck, T
    McEvoy, J
    Lieberman, J
    SCHIZOPHRENIA RESEARCH, 2005, 80 (01) : 1 - 8
  • [3] Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial
    Richard S E Keefe
    Robert M Bilder
    Philip D Harvey
    Sonia M Davis
    Barton W Palmer
    James M Gold
    Herbert Y Meltzer
    Michael F Green
    Del D Miller
    Jose M Canive
    Lawrence W Adler
    Theo C Manschreck
    Marvin Swartz
    Robert Rosenheck
    Diana O Perkins
    Trina M Walker
    T Scott Stroup
    Joseph P McEvoy
    Jeffrey A Lieberman
    Neuropsychopharmacology, 2006, 31 : 2033 - 2046
  • [4] Baseline neurocognitive deficits in the CATIE schizophrenia trial
    Keefe, Richard S. E.
    Bilder, Robert M.
    Harvey, Philip D.
    Davis, Sonia M.
    Palmer, Barton W.
    Gold, James M.
    Meltzer, Herbert Y.
    Green, Michael F.
    Miller, Del D.
    Canive, Jose M.
    Adler, Lawrence W.
    Manschreck, Theo C.
    Swartz, Marvin
    Rosenheck, Robert
    Perkins, Diana O.
    Walker, Trina M.
    Stroup, T. Scott
    McEvoy, Joseph P.
    Lieberman, Jeffrey A.
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 (09) : 2033 - 2046
  • [5] Low rates of treatment for metabolic disorders in the CATIE schizophrenia trial at baseline
    Nasrallah, HA
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S204 - S204
  • [6] Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial
    Miller, DD
    McEvoy, JP
    Davis, SM
    Caroff, SN
    Saltz, BL
    Chakos, MH
    Swartz, MS
    Keefe, RSE
    Rosenheck, RA
    Stroup, TS
    Lieberman, JA
    SCHIZOPHRENIA RESEARCH, 2005, 80 (01) : 33 - 43
  • [7] Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial
    Chakos, Miranda H.
    Glick, Ira D.
    Miller, Alexander L.
    Hamner, Mark B.
    Miller, Del D.
    Patel, Jayendra K.
    Tapp, Andre
    Keefe, Richard S. E.
    Rosenheck, Robert A.
    PSYCHIATRIC SERVICES, 2006, 57 (08) : 1094 - 1101
  • [8] The CATIE schizophrenia effectiveness trial
    DeLisi, LE
    Nasrallah, HA
    SCHIZOPHRENIA RESEARCH, 2005, 80 (01) : V - VI
  • [9] Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline
    Nasrallah, Henry A.
    Meyer, Jonathan M.
    Goff, Donald C.
    McEvoy, Joseph P.
    Davis, Sonia M.
    Stroup, I. Scott
    Lieberman, Jeffrey A.
    SCHIZOPHRENIA RESEARCH, 2006, 86 (1-3) : 15 - 22
  • [10] Results of phase 3 of the CATIE schizophrenia trial
    Stroup, T. Scott
    Lieberman, Jeffrey A.
    McEvoy, Joseph R.
    Davis, Sonia M.
    Swartz, Marvin S.
    Keefe, Richard S. E.
    Miller, Alexander L.
    Rosenheck, Robert A.
    Hsiao, John K.
    SCHIZOPHRENIA RESEARCH, 2009, 107 (01) : 1 - 12
12345